Editing Antidepressant (section)

===Eating disorders===
Antidepressants are recommended as an alternative or additional first step to self-help programs in the treatment of [[bulimia nervosa]].<ref name="urlwww.nice.org.uk2">{{cite web|url=http://www.nice.org.uk/nicemedia/pdf/CG9FullGuideline.pdf|title=Eating disorders in over 8s: management|date=28 January 2004|work=Clinical guideline [CG9]|publisher=National Institute for Health Care Excellence (NICE)|location=United Kingdom|url-status=live|archive-url=https://web.archive.org/web/20140327055429/http://www.nice.org.uk/nicemedia/pdf/CG9FullGuideline.pdf|archive-date=27 March 2014}}</ref> SSRIs (fluoxetine in particular) are preferred over other antidepressants due to their acceptability, tolerability, and superior reduction of symptoms in short-term trials. Long-term efficacy remains poorly characterized. [[Bupropion]] is not recommended for the treatment of eating disorders, due to an increased risk of seizure.<ref>{{cite web|url=https://www.nlm.nih.gov/medlineplus/druginfo/meds/a695033.html|title=Bupropion: MedlinePlus Drug Information|access-date=24 May 2016|url-status=live|archive-url=https://web.archive.org/web/20160508110157/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a695033.html|archive-date=8 May 2016}}</ref>

Similar recommendations apply to [[binge eating disorder]].<ref name="urlwww.nice.org.uk2" /> SSRIs provide short-term reductions in binge eating behavior, but have not been associated with significant weight loss.<ref name="urlNational Guideline Clearinghouse | Practice guideline for the treatment of patients with eating disorders.">{{cite web|url=http://www.guidelines.gov/content.aspx?id=9318+|work=National Guideline Clearinghouse|publisher=Agency for Healthcare Research and Quality|title=Practice guideline for the treatment of patients with eating disorders|url-status=dead|archive-url=https://web.archive.org/web/20130525135033/http://www.guidelines.gov/content.aspx?id=9318+|archive-date=25 May 2013|date=5 July 2018}}</ref>

Clinical trials have generated mostly negative results for the use of SSRIs in the treatment of [[anorexia nervosa]].<ref name="pmid21414249">{{cite journal|vauthors=Flament MF, Bissada H, Spettigue W|title=Evidence-based pharmacotherapy of eating disorders|journal=Int. J. Neuropsychopharmacol.|volume=15|issue=2|pages=189–207|date=March 2012|pmid=21414249|doi=10.1017/S1461145711000381|doi-access=free}}</ref> Treatment guidelines from the National Institute of Health and Care Excellence (NICE)<ref name="urlwww.nice.org.uk2" /> recommend against the use of SSRIs in this disorder. Those from the American Psychiatric Association (APA) note that SSRIs confer no advantage regarding weight gain, but may be used for the treatment of co-existing depressive, anxiety, or obsessive–compulsive disorders.<ref name="urlNational Guideline Clearinghouse | Practice guideline for the treatment of patients with eating disorders." />